Product Code: PHA1300
The global Epilepsy Therapeutics market is projected to grow at a CAGR of 8.1% by 2034.
“The Epilepsy Therapeutics Market Report 2024-2034”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Medical Advances Driving Epilepsy Treatment Market Growth
In the ever-evolving field of medical progress, initiatives and innovations in epilepsy treatment are playing a pivotal role in reshaping patient care paradigms. Globally, government-backed endeavors and cutting-edge developments in drugs and treatments are fostering an environment of unprecedented growth in the epilepsy treatment market. A notable initiative occurred when NYU Langone Health secured an $8 million grant from the National Institutes of Health (NIH) in February 2022. The funds are earmarked to develop an innovative implantable monitoring device designed to capture unprecedented data on brain activity during seizures. Led by Dr. Daniel Friedman at NYU Langone's Comprehensive Epilepsy Center, the project addresses the limitations of outdated technology, presenting an opportunity to build an ultrathin device with thousands of measurement contacts. This NIH UG3/UH3-funded initiative involves collaboration with institutions such as New York University's Center for Neural Science, Duke University, the University of Utah, and Blackrock Neurotech.
Designed by Dr. Jonathan Viventi from Duke University, the implant utilizes flexible liquid crystal polymer thermoplastic material and a network of circuits connecting hundreds to thousands of electrodes for high-density sampling of microsignals from extensive brain areas. Successfully tested intraoperatively, the device is poised for clinical use with the capacity for implantation for up to 30 days. As part of the NIH's Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, this collaborative effort places NYU Langone Health at the forefront of transformative advancements in epilepsy care. Clinical trials employing an FDA-approved monitoring implant are expected to commence in 2023, contributing to the growth of the epilepsy treatment market by fostering groundbreaking advancements in laser ablation, high-precision surgeries, and overall improvements in epilepsy treatment outcomes.
Socioeconomic Disparities and Technological Challenges
A global concern is the accessibility of anti-seizure medication, with many individuals facing difficulties in affording or obtaining multiple medication options, as emphasized in the August 2022 report, 'Survey on the worldwide availability and affordability of anti-seizure medications: Report of the ILAE Task Force on Access to Treatment.' Beyond medication-related challenges, demographic factors contribute significantly to differences in the quality of life and care experiences of individuals. Studies conducted in the United States and North America reveal disparities in seizure control rates and epilepsy remission along racial and ethnic lines. Additionally, there are delays in diagnosis and reduced utilization of epilepsy surgery in specific minority populations.
Furthermore, as highlighted in an article published in December 2022 by NIH, the impact of socioeconomic and racial divides extends to rates of sudden unexpected death in epilepsy (SUDEP). Individuals facing high socioeconomic disadvantage exhibit higher rates of SUDEP, persisting even during periods of decreasing overall SUDEP rates. The identified barriers to care, including medication affordability and access to primary and specialist care, demand comprehensive solutions that extend beyond the healthcare sector. Addressing these issues necessitates not only healthcare interventions but also broader political, economic, and systemic changes. While promising strategies like telehealth services are emerging, sustainable solutions will require coordinated efforts involving individuals, communities, healthcare institutions, and governmental and non-governmental organizations. This underscores the complex and multifaceted nature of the challenges in epilepsy care.
What Questions Should You Ask before Buying a Market Research Report?
- How is the epilepsy therapeutics market evolving?
- What is driving and restraining the epilepsy therapeutics market?
- How will each epilepsy therapeutics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
- How will the market shares for each epilepsy therapeutics submarket develop from 2024 to 2034?
- What will be the main driver for the overall market from 2024 to 2034?
- Will leading epilepsy therapeutics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
- Who are the leading players and what are their prospects over the forecast period?
- What are the epilepsy therapeutics projects for these leading companies?
- How will the industry evolve during the period between 2024 and 2034? What are the implications of epilepsy therapeutics projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further the epilepsy therapeutics?
- Where is the epilepsy therapeutics market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Epilepsy Therapeutics Market today, and over the next 10 years:
- Our 215-page report provides 91 tables, 119 charts /graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them - NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the Epilepsy Therapeutics Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2034 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising epilepsy therapeutics prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.
Segments Covered in the Report:
Drug Class
- First Generation Drugs
- Second Generation Drugs
- Third Generation Drugs
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 25 leading national markets:
North America
Europe
- Germany
- UK
- France
- Spain
- Italy
- Sweden
- Switzerland
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Singapore
- Taiwan
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
MEA
- GCC
- South Africa
- Rest of MEA
The report also includes profiles and for some of the leading companies in the Epilepsy Therapeutics Market, 2024 to 2034, with a focus on this segment of these companies' operations.
Leading companies profiled in the report:
- Eisai, Inc.
- GlaxoSmithKline (GSK)
- GW Pharma
- Merk KGaA
- Neurocrine Biosciences, Inc.
- Novartis AG
|
- Ovid Therapeutics
- Pfizer Inc
- Praxis Precision Medicines
- Sanofi
- UCB S.A.
|
Overall world revenue for Epilepsy Therapeutics Market, 2024 to 2034 in terms of value the market will surpass US$9,800 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the “Epilepsy Therapeutics Market, 2024 to 2034” report help you?
In summary, our 210+ page report provides you with the following knowledge:
- Revenue forecasts to 2034 for Epilepsy Therapeutics Market, 2024 to 2034, with forecasts for drug class and distribution channel each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2034 for five regional and 25 key national markets - See forecasts for the Epilepsy Therapeutics Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Germany, UK, France, Spain, Italy, Sweden, Switzerland, China, India, Japan, Australia, South Korea, Singapore, Taiwan, Brazil, Mexico, Argentina, GCC, South Africa, and among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 10 of the major companies involved in the Epilepsy Therapeutics Market, 2024 to 2034.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Epilepsy Therapeutics Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.
Table of Contents
1 Report Overview
- 1.1 Objectives of the Study
- 1.2 Introduction to Epilepsy Therapeutics Market
- 1.3 What This Report Delivers
- 1.4 Why You Should Read This Report
- 1.5 Key Questions Answered by This Analytical Report
- 1.6 Who is This Report for?
- 1.7 Methodology
- 1.7.1 Market Definitions
- 1.7.2 Market Evaluation & Forecasting Methodology
- 1.7.3 Data Validation
- 1.7.3.1 Primary Research
- 1.7.3.2 Secondary Research
- 1.8 Frequently Asked Questions (FAQs)
- 1.9 Associated Visiongain Reports
- 1.10 About Visiongain
2 Executive Summary
3 Market Overview
- 3.1 Key Findings
- 3.2 Market Dynamics
- 3.2.1 Market Driving Factors
- 3.2.1.1 Transforming Brain Tumour-Related Epilepsy through Innovative Gene Therapy Approaches
- 3.2.1.2 Uncovering Novel Possibilities in a Rare Form of Childhood Epilepsy Treatment
- 3.2.1.3 Advancements, Global Investments, and Medical Advances Drive Epilepsy Treatment Market Growth
- 3.2.1.4 Surge in Epilepsy Prevalence
- 3.2.2 Market Restraining Factors
- 3.2.2.1 Seizure Recognition Challenges
- 3.2.2.2 Socioeconomic Disparities and Technological Challenges
- 3.2.2.3 Patent Expiry
- 3.2.3 Market Opportunities
- 3.2.3.1 Innovating Antiepileptic Therapies for Drug-Resistant Cases
- 3.2.3.2 Inhibitory Neurons Transform Focal Epilepsy Treatment
- 3.3 COVID-19 Impact Analysis
- 3.4 Porter's Five Forces Analysis
- 3.4.1 Bargaining Power of Suppliers
- 3.4.2 Bargaining Power of Buyers
- 3.4.3 Competitive Rivalry
- 3.4.4 Threat from Substitutes
- 3.4.5 Threat of New Entrants
- 3.5 PEST Analysis
4 Epilepsy Therapeutics Market Analysis by Drug Class
- 4.1 Key Findings
- 4.2 Drug Class Segment: Market Attractiveness Index
- 4.3 Epilepsy Therapeutics Market Size Estimation and Forecast by Drug Class
- 4.4 First Generation Drugs
- 4.4.1 Market Size by Region, 2024-2034 (US$ Million)
- 4.4.2 Market Share by Region, 2024 & 2034 (%)
- 4.5 Second Generation Drugs
- 4.5.1 Market Size by Region, 2024-2034 (US$ Million)
- 4.5.2 Market Share by Region, 2024 & 2034 (%)
- 4.6 Third Generation Drugs
- 4.6.1 Market Size by Region, 2024-2034 (US$ Million)
- 4.6.2 Market Share by Region, 2024 & 2034 (%)
5 Epilepsy Therapeutics Market Analysis by Distribution Channel
- 5.1 Key Findings
- 5.2 Distribution Channel Segment: Market Attractiveness Index
- 5.3 Epilepsy Therapeutics Market Size Estimation and Forecast by Distribution Channel
- 5.4 Hospital Pharmacy
- 5.4.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.4.2 Market Share by Region, 2024 & 2034 (%)
- 5.5 Retail Pharmacy
- 5.5.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.5.2 Market Share by Region, 2024 & 2034 (%)
- 5.6 Online Pharmacy
- 5.6.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.6.2 Market Share by Region, 2024 & 2034 (%)
6 Epilepsy Therapeutics Market Analysis by Region
- 6.1 Key Findings
- 6.2 Regional Market Size Estimation and Forecast
7 North America Epilepsy Therapeutics Market Analysis
- 7.1 Key Findings
- 7.2 North America Epilepsy Therapeutics Market Attractiveness Index
- 7.3 North America Epilepsy Therapeutics Market by Country, 2024, 2029 & 2034 (US$ Million)
- 7.4 North America Epilepsy Therapeutics Market Size Estimation and Forecast by Country
- 7.5 North America Epilepsy Therapeutics Market Size Estimation and Forecast by Drug Class
- 7.6 North America Epilepsy Therapeutics Market Size Estimation and Forecast by Distribution Channel
- 7.7 U.S. Epilepsy Therapeutics Market Analysis
- 7.8 Canada Epilepsy Therapeutics Market Analysis
8 Europe Epilepsy Therapeutics Market Analysis
- 8.1 Key Findings
- 8.2 Europe Epilepsy Therapeutics Market Attractiveness Index
- 8.3 Europe Epilepsy Therapeutics Market by Country, 2024, 2029 & 2034 (US$ Million)
- 8.4 Europe Epilepsy Therapeutics Market Size Estimation and Forecast by Country
- 8.5 Europe Epilepsy Therapeutics Market Size Estimation and Forecast by Drug Class
- 8.6 Europe Epilepsy Therapeutics Market Size Estimation and Forecast by Distribution Channel
- 8.7 Germany Epilepsy Therapeutics Market Analysis
- 8.8 France Epilepsy Therapeutics Market Analysis
- 8.9 UK Epilepsy Therapeutics Market Analysis
- 8.10 Italy Epilepsy Therapeutics Market Analysis
- 8.11 Spain Epilepsy Therapeutics Market Analysis
- 8.12 Sweden Epilepsy Therapeutics Market Analysis
- 8.13 Switzerland Epilepsy Therapeutics Market Analysis
- 8.14 Rest of Europe Epilepsy Therapeutics Market Analysis
9 Asia Pacific Epilepsy Therapeutics Market Analysis
- 9.1 Key Findings
- 9.2 Asia Pacific Epilepsy Therapeutics Market Attractiveness Index
- 9.3 Asia Pacific Epilepsy Therapeutics Market by Country, 2024, 2029 & 2034 (US$ Million)
- 9.4 Asia Pacific Epilepsy Therapeutics Market Size Estimation and Forecast by Country
- 9.5 Asia Pacific Epilepsy Therapeutics Market Size Estimation and Forecast by Drug Class
- 9.6 Asia Pacific Epilepsy Therapeutics Market Size Estimation and Forecast by Distribution Channel
- 9.7 Japan Epilepsy Therapeutics Market Analysis
- 9.8 China Epilepsy Therapeutics Market Analysis
- 9.9 India Epilepsy Therapeutics Market Analysis
- 9.10 Australia Epilepsy Therapeutics Market Analysis
- 9.11 South Korea Epilepsy Therapeutics Market Analysis
- 9.12 Singapore Epilepsy Therapeutics Market Analysis
- 9.13 Taiwan Epilepsy Therapeutics Market Analysis
- 9.14 Rest of Asia Pacific Epilepsy Therapeutics Market Analysis
10 Latin America Epilepsy Therapeutics Market Analysis
- 10.1 Key Findings
- 10.2 Latin America Epilepsy Therapeutics Market Attractiveness Index
- 10.3 Latin America Epilepsy Therapeutics Market by Country, 2024, 2029 & 2034 (US$ Million)
- 10.4 Latin America Epilepsy Therapeutics Market Size Estimation and Forecast by Country
- 10.5 Latin America Epilepsy Therapeutics Market Size Estimation and Forecast by Drug Class
- 10.6 Latin America Epilepsy Therapeutics Market Size Estimation and Forecast by Distribution Class
- 10.7 Brazil Epilepsy Therapeutics Market Analysis
- 10.8 Mexico Epilepsy Therapeutics Market Analysis
- 10.9 Argentina Epilepsy Therapeutics Market Analysis
- 10.10 Rest of Latin America Epilepsy Therapeutics Market Analysis
11 MEA Epilepsy Therapeutics Market Analysis
- 11.1 Key Findings
- 11.2 MEA Epilepsy Therapeutics Market Attractiveness Index
- 11.3 MEA Epilepsy Therapeutics Market by Country, 2024, 2029 & 2034 (US$ Million)
- 11.4 MEA Epilepsy Therapeutics Market Size Estimation and Forecast by Country
- 11.5 MEA Epilepsy Therapeutics Market Size Estimation and Forecast by Drug Class
- 11.6 MEA Epilepsy Therapeutics Market Size Estimation and Forecast by Application
- 11.7 GCC Epilepsy Therapeutics Market Analysis
- 11.8 South Africa Epilepsy Therapeutics Market Analysis
- 11.9 Rest of MEA Epilepsy Therapeutics Market Analysis
12 Company Profiles
- 12.1 Competitive Landscape, 2022
- 12.2 Strategic Outlook
- 12.1 Eisai, Inc.
- 12.1.1 Company Snapshot
- 12.1.2 Company Overview
- 12.1.3 Financial Analysis
- 12.1.3.1 Net Revenue, 2017-2022
- 12.1.3.2 Regional Market Shares, 2022
- 12.1.4 Product Benchmarking
- 12.1.5 Strategic Outlook
- 12.2 GlaxoSmithKline (GSK)
- 12.2.1 Company Snapshot
- 12.2.2 Company Overview
- 12.2.3 Financial Analysis
- 12.2.3.1 Net Revenue, 2017-2022
- 12.2.3.2 R&D, 2017-2022
- 12.2.3.3 Regional Market Shares, 2022
- 12.2.4 Product Benchmarking
- 12.2.5 Strategic Outlook
- 12.3 GW Pharma
- 12.3.1 Company Snapshot
- 12.3.2 Company Overview
- 12.3.3 Product Benchmarking
- 12.3.4 Strategic Outlook
- 12.4 Pfizer Inc
- 12.4.1 Company Snapshot
- 12.4.2 Company Overview
- 12.4.3 Financial Analysis
- 12.4.3.1 Net Revenue, 2017-2022
- 12.4.3.2 R&D, 2017-2022
- 12.4.3.3 Regional Market Shares, 2022
- 12.4.4 Product Benchmarking
- 12.4.5 Strategic Outlook
- 12.5 Sanofi
- 12.5.1 Company Snapshot
- 12.5.2 Company Overview
- 12.5.3 Financial Analysis
- 12.5.3.1 Net Revenue, 2017-2022
- 12.5.3.2 R&D, 2017-2022
- 12.5.3.3 Regional Market Shares, 2022
- 12.5.4 Product Benchmarking
- 12.5.5 Strategic Outlook
- 12.6 UCB S.A.
- 12.6.1 Company Snapshot
- 12.6.2 Company Overview
- 12.6.3 Financial Analysis
- 12.6.3.1 Net Revenue, 2017-2022
- 12.6.3.2 R&D, 2017-2022
- 12.6.3.3 Regional Market Shares, 2022
- 12.6.4 Product Benchmarking
- 12.6.5 Strategic Outlook
- 12.7 Novartis AG
- 12.7.1 Company Snapshot
- 12.7.2 Company Overview
- 12.7.3 Financial Analysis
- 12.7.3.1 Net Revenue, 2017-2022
- 12.7.3.2 R&D, 2017-2022
- 12.7.3.3 Regional Market Shares, 2022
- 12.7.4 Product Benchmarking
- 12.7.5 Strategic Outlook
- 12.8 Merck KGaA
- 12.8.1 Company Snapshot
- 12.8.2 Company Overview
- 12.8.3 Financial Analysis
- 12.8.3.1 Net Revenue, 2017-2022
- 12.8.3.2 R&D, 2017-2022
- 12.8.3.3 Regional Market Shares, 2022
- 12.8.4 Product Benchmarking
- 12.8.5 Strategic Outlook
- 12.9 Ovid Therapeutics
- 12.9.1 Company Snapshot
- 12.9.2 Company Overview
- 12.9.3 Product Benchmarking
- 12.9.4 Strategic Outlook
- 12.10 Praxis Precision Medicines
- 12.10.1 Company Snapshot
- 12.10.2 Company Overview
- 12.10.3 Product Benchmarking
- 12.10.4 Strategic Outlook
- 12.11 Neurocrine Biosciences, Inc.
- 12.11.1 Company Snapshot
- 12.11.2 Company Overview
- 12.11.3 Financial Analysis
- 12.11.3.1 Net Revenue, 2017-2022
- 12.11.3.2 R&D, 2017-2022
- 12.11.4 Product Benchmarking
- 12.11.5 Strategic Outlook
- 12.12 Neurelis, Inc.
- 12.12.1 Company Snapshot
- 12.12.2 Company Overview
- 12.12.3 Product Benchmarking
- 12.12.4 Strategic Outlook
13 Conclusion and Recommendations
- 13.1 Concluding Remarks from Visiongain
- 13.2 Recommendations for Market Players